Types of Pancreatic Cancer and Survival Rates: How Pancreatic Ductal Adenocarcinoma Differs from Steve Jobs’s Neuroendocrine Tumor (PNET)

Many people have wondered: “If Apple co-founder Steve Jobs had pancreatic cancer, how did he live for 8 years after his diagnosis?” or “Why was an acquaintance told their pancreatic tumor had a good outlook with surgery?”

In everyday conversation, “pancreatic cancer” almost always refers to invasive pancreatic ductal adenocarcinoma (PDAC), which accounts for about 90% of all pancreatic malignancies and arises from the exocrine ducts that carry digestive juices. However, the pancreas also contains hormone-producing endocrine cells (the islets of Langerhans), which give rise to a different family of tumors called pancreatic neuroendocrine tumors (PNET / PanNET; a few percent — under 2% of pancreatic cancers in American Cancer Society statistics), alongside rarer types such as acinar cell carcinoma and solid pseudopapillary neoplasms (SPN).

In this article, we compare:

• How tumors arising from the pancreas’s “two factories” (exocrine ducts vs. endocrine islets) differ in growth speed, 5-year survival rate, and treatment
• Functional PNETs (insulinoma, gastrinoma) vs. non-functional PNETs, and WHO grading (NET G1, G2, G3 vs. NEC)
• Why Steve Jobs lived 8 years with a PNET, and what oncology studies show about delaying or refusing standard treatment in favor of alternative therapies
• Modern treatments for PNET, including everolimus, sunitinib, and Peptide Receptor Radionuclide Therapy (PRRT: ¹⁷⁷Lu-dotatate / Lutathera)

This article does not replace medical diagnosis or treatment. Always confirm your exact pathology classification and treatment options with your oncologist.

Conclusion: Common Ductal Adenocarcinoma (~90%) and Steve Jobs’s PNET (a Few Percent) Are Biologically Distinct Diseases

• The pancreas has two distinct functions: exocrine (~95% of volume, making digestive enzymes) and endocrine (~1–2% of volume, making hormones like insulin). Exocrine ducts give rise to pancreatic ductal adenocarcinoma (PDAC, ~90%), whereas endocrine islets give rise to pancreatic neuroendocrine tumors (PNET, a few percent).
• Survival rates and growth speeds differ dramatically. Overall 5-year relative survival for pancreatic cancer in Japan is 13.2% (though the Japan Pancreas Society registry reports 80.4% for tumors ≤10 mm). By contrast, well-differentiated PNETs (NET G1/G2) often grow slowly; in US data, 5-year relative survival is ~91% when localized, ~19% with distant spread, and ~48% across all stages.
• Steve Jobs was diagnosed in October 2003 with a PNET, not common PDAC. It was found incidentally on an abdominal CT, and his doctors urged prompt surgery. However, Jobs postponed surgery for about 9 months while pursuing a strict vegan, fruit- and juice-heavy diet and other alternative therapies, undergoing resection in July 2004.
• PNET treatments have advanced rapidly, including somatostatin analogs, targeted agents (everolimus, sunitinib), and PRRT (¹⁷⁷Lu-dotatate / Lutathera, approved in Japan in 2021), which delivers beta-radiation directly to somatostatin-receptor-positive tumor cells.

Comparison of Pancreatic Tumor Types, Share, 5-Year Survival, and Treatments

Sources: Japan Pancreas Society Registry (Egawa 2004, 2012); National Cancer Center Japan; Japan Neuroendocrine Tumor Society (JNETS) Guidelines; American Cancer Society, “Survival Rates for Pancreatic Neuroendocrine Tumor” (SEER data for diagnoses 2015–2021). Shares and survival rates vary by country, period, and staging definitions, so treat them as approximate.

Functional vs. Non-Functional PNETs

PNETs (now also grouped under the umbrella term “pancreatic NEN” in guidelines) are divided by whether they produce hormone symptoms.

• Functional PNETs (roughly 10–40% depending on the report): Secrete excess hormones that cause distinctive clinical syndromes even when the tumor is small — such as insulinoma (the most common; fasting or exercise-related hypoglycemia with sweating, palpitations, tremors, and confusion relieved by sugar; ~90% benign or low-grade and curable by surgery), gastrinoma (Zollinger-Ellison syndrome: refractory peptic ulcers and watery diarrhea; more than half have malignant potential and spread to lymph nodes or the liver), and glucagonoma, VIPoma, and somatostatinoma (characteristic rash — necrolytic migratory erythema — diabetes, or profuse watery diarrhea).
• Non-Functional PNETs (roughly 60–90%): Do not cause hormone syndromes and are increasingly discovered incidentally on ultrasound, CT, or MRI during health checkups. When found small, surgery offers a good chance of cure.

Under the WHO classification, PNETs are graded by how fast the cells proliferate (Ki-67 index and mitotic count): NET G1 (Ki-67 under 3%), NET G2 (3–20%), and NET G3 (over 20%) are well-differentiated, while neuroendocrine carcinoma (NEC) is poorly differentiated, has a different genetic background, and progresses quickly. The grade guides drug selection.

Why Steve Jobs Lived 8 Years — and What Studies Show About Delaying Standard Treatment

Steve Jobs’s course (1955–2011) is widely known from his authorized biography by Walter Isaacson and press reports. His detailed pathology and medical records have not been made public, so the following is based on the biography and reporting.

1. October 2003 — Incidental discovery of a PNET: During an abdominal CT scan related to kidney stones, doctors found a shadow on Steve Jobs’s pancreas. Biopsy showed a pancreatic neuroendocrine tumor (PNET) — a minority type that often progresses relatively slowly — not standard PDAC. His physicians urged prompt surgical resection.
2. About nine months of alternative therapy: Reluctant to undergo surgery, Jobs postponed it for about 9 months. According to the biography, he relied on a strict vegan diet with large quantities of fresh fruit and carrot juices (close to a fruitarian diet), acupuncture, herbal remedies, and bowel cleansings. (As noted in our article on fruit and fructose, actor Ashton Kutcher has said he was hospitalized with pancreas problems after imitating this fruit-only diet for a film role.)
3. July 2004 surgery and subsequent liver metastasis: After a CT scan suggested the tumor had grown and possibly spread, Jobs underwent a modified Whipple procedure (pancreaticoduodenectomy) at Stanford on July 31, 2004; according to the biography, small liver metastases were found during the operation. The liver disease later progressed, and after a liver transplant from a deceased donor in 2009 and drug therapy, he died in October 2011 at age 56 — 8 years after diagnosis.

Survival data on choosing alternative medicine over standard treatment

Two analyses of the US National Cancer Database by Johnson et al. at Yale examined patients with non-metastatic breast, prostate, lung, or colorectal cancer — pancreatic tumors were not included:

• Patients who chose alternative medicine alone without any conventional treatment had about a 2.5-fold higher risk of death than those receiving conventional treatment (HR 2.50; JNCI 2018, PMID: 28922780).
• Patients who used complementary medicine alongside conventional treatment were much more likely to refuse parts of it (surgery, chemotherapy, radiotherapy, or hormone therapy) and had about a 2.1-fold higher risk of death (HR 2.08). Once treatment refusal and delay were accounted for, the difference was no longer significant, suggesting the excess risk was driven by refusing standard therapy (JAMA Oncol 2018, PMID: 30027204).

Whether operating 9 months earlier would have changed Jobs’s outcome cannot be determined, because his pathology details are not public. Still, because localized PNETs often do well when resected, his case is frequently cited as an illustration of the risks of postponing standard treatment. If you want to try a diet or supplement, do not stop or delay standard treatment — discuss it with your doctor first.

Modern Testing and Therapy for PNET: PRRT (¹⁷⁷Lu-Dotatate / Lutathera)

Most well-differentiated PNETs express many somatostatin receptors (SSTR) on their cell surface, and tests and treatments that exploit this property are available in Japan.

1. Somatostatin receptor scintigraphy (OctreoScan): A somatostatin-like compound tagged with a small amount of radioactive isotope is injected to show where PNET lesions are located throughout the body.
2. Targeted agents (everolimus / Afinitor, sunitinib / Sutent) and streptozocin (Zanosar): Oral drugs that block tumor growth signals (the mTOR pathway and angiogenesis), and an intravenous drug for pancreatic and gastrointestinal NETs, are approved.
3. Peptide Receptor Radionuclide Therapy (PRRT: ¹⁷⁷Lu-dotatate / Lutathera, approved in Japan in 2021): A somatostatin analog linked to the beta-emitting radionuclide Lutetium-177, which irradiates only a few millimeters around it. Infused intravenously, it binds to receptor-positive tumor cells and irradiates them from within. In phase 3 trials, NETTER-1 (2017, in midgut NETs) reduced the risk of progression or death by about 79% (HR 0.21), and NETTER-2 (2024, first-line in higher-grade G2 [Ki-67 ≥10%] to G3 gastroenteropancreatic NETs, including pancreatic tumors) reduced it by about 72% (HR 0.276). The primary endpoint in both was progression-free survival; the final NETTER-1 analysis did not show a statistically significant overall survival benefit. It is used for eligible patients after receptor positivity is confirmed by imaging.

Pancreatic Cancer Series: Related Articles

• Alcohol and Pancreatic Cancer: Drinking Amounts, 66-Year Trends, and Latest Treatments
• What Foods Are Linked to Pancreatic Cancer? Sugar, Fructose, Coffee, Processed Meat, and Oils
• Diabetes and Pancreatic Cancer: Why Sudden Blood Sugar Worsening Can Be an Early Sign, plus GLP-1 Drugs
• Why Is Pancreatic Cancer Hard to Find? Early Symptoms, Pancreatic Cysts (IPMN), Ultrasound Limits, and the APOA2-i Blood Test
• Periodontal Disease, Blood Type, and Genetics in Pancreatic Cancer: Blood Type O, Oral Bacteria, and BRCA
• Acute and Chronic Pancreatitis and Pancreatic Cancer: Alcohol, Gallstones, Triglycerides, and Post-Surgery MCT Oil
• Latest Treatments for Pancreatic Cancer: Conversion Surgery, NALIRIFOX, KRAS Inhibitors, Carbon-Ion Radiotherapy, and mRNA Vaccines

References

• Japan Neuroendocrine Tumor Society (JNETS). Clinical Practice Guidelines for Pancreatic and Gastrointestinal Neuroendocrine Neoplasms (NEN), 2nd ed. Kanehara & Co.
• Japan Pancreas Society. Clinical Practice Guidelines for Pancreatic Cancer 2025. Kanehara & Co., 2025.
• National Cancer Center Japan, Rare Cancer Center. “Pancreatic and gastrointestinal neuroendocrine tumors” (Japanese). https://www.ncc.go.jp/jp/rcc/about/neuroendocrine_tumor_2/index.html
• American Cancer Society. Survival Rates for Pancreatic Neuroendocrine Tumor. https://www.cancer.org/cancer/types/pancreatic-neuroendocrine-tumor/detection-diagnosis-staging/survival-rates.html
• Egawa S, et al. Clinicopathological aspects of small pancreatic cancer. Pancreas. 2004;28(3):235-240. (PMID: 15084963) / Egawa S, et al. Japan Pancreatic Cancer Registry; 30th year anniversary. Pancreas. 2012;41(7):985-992. (PMID: 22750974)
• Isaacson W. Steve Jobs. Simon & Schuster; 2011.
• Strosberg J, et al. Phase 3 Trial of ¹⁷⁷Lu-Dotatate for Midgut Neuroendocrine Tumors (NETTER-1). N Engl J Med. 2017;376(2):125-135. (PMID: 28076709)
• Singh S, et al. (NETTER-2). Lancet. 2024;403(10446):2807-2817. (PMID: 38851203)
• Johnson SB, et al. Use of Alternative Medicine for Cancer and Its Impact on Survival. J Natl Cancer Inst. 2018;110(1):121-124. (PMID: 28922780)
• Johnson SB, et al. Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers. JAMA Oncol. 2018;4(10):1375-1381. (PMID: 30027204)